Earlier this year I talked about the President’s Precision Medicine Initiative, which detailed a path to provide Americans with stronger customized medicine thanks to genetic research.

We saw an entire industry pop up overnight when the FDA told Big Genomics company 23andMe it had to sell its health data to drug and biotech companies.

Essentially this means that anytime a patient gets his or her blood drawn, spits in a cup, or gets a biopsy, medical teams can use this information to develop stronger datasets to diagnose and treat ailments.

And while the Precision Medicine Initiative hasn’t cured major diseases across the board just yet, we’re starting to see some preliminary wins.

Last week the FDA approved Orkambi, a combination of two drugs that repairs faulty proteins in patients who suffer from cystic fibrosis.

And later this month the FDA is looking to approve a new class of cholesterol-lowering medication called PCSK-9 inhibitors. The cool thing is, they developed this based on the information gathered from people with naturally high and naturally low cholesterol levels to determine what the characteristics are of each.

Finally there’s the new field of immunotherapies, which stimulates a body’s own immune system to attack disease based on advanced genetic testing. This approach relies on matching a treatment with whatever faulty DNA is causing the disease.

Even with all the breakthroughs, precision medicine still has its critics. They argue people need to make lifestyle changes to overcome diseases. But by this point, we know that doesn’t necessarily work for the most advanced diseases.

Whatever the case, precision medicine is sticking around for the foreseeable future, and is still quickly gaining momentum.

Ben Benoy

Ben Benoy
Editor, BioTech Intel Trader

How to Prep Your Retirement Savings for 2020

“This is no longer a question of ‘if’ but simply a question of ‘when.’” Harry Dent opens up about his latest forecast for 2020 and how a number of factors could lead… Read More>>
Ben Benoy
Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.